Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Vaxart Shares Rise 95% After Signing Agreement for Oral Tablet COVID-19 Vaccine

Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually. Clinical-stage biotechnology...
Streetwise Reports | June 26, 2020 |

BioNTech, CureVac, Valeo Pharma - the license to print money

Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because ther...
Mario Hose | August 24, 2020 |

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the...
Mario Hose | July 29, 2020 |

Biotech Identifies Antibody with 100% SARS-CoV-2 Inhibition

The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report. In a May 26 research note, Dawson James analyst Jason Kolbert reported that Sorrento Therape...
Streetwise Reports | May 28, 2020 |

Top Pick Status Given to Small-Cap with Pain Drug Candidate

The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. In a July 10 research note, analyst Douglas Loe reported that Echelon Wealth Partners bestowed Top Pick status on Antibe Therapeutics Inc. (ATE:TSX.V...
Streetwise Reports | July 19, 2019 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |

iBio Shares Trade Up 40% After Announcing Development of Proprietary COVID-19 Vaccine Candidates

iBio Inc. shares traded higher after the company reported that it has filed several provisional patents for its SARS-CoV-2 Virus-Like Particle platform with the U.S. Patent and Trademark Office. Biologics contract manufacturing firm iBio Inc. (IBIO:NYSE.Ame...
Streetwise Reports | March 19, 2020 |

California Biotech Partners for Manufacture of COVID-19 Vaccine Candidate

Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report. In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnersh...
Streetwise Reports | May 7, 2020 |

Acceleration of COVID-19 Vaccine Programs Could Benefit U.S. Biotech

The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report. In a May 8 research note, H.C. Wainwright & Co. analyst Ram Selvaraju wrote that the efforts being made in general to accelerate deve...
Streetwise Reports | May 14, 2020 |

Could DehydraTECH CBD be Worth $3 Billion a Year to Lexaria?

PCG Digital -- Hypertension, or high blood pressure as it's commonly known, affects over three million Americans every year and is a primary or contributing cause of death for 25% of them. On a global scale, hypertension kills roughly 7.6 milli on people per year . L...
Featured Submission | March 9, 2021 |
1 2 3 4 5 6